Home>>Signaling Pathways>> DNA Damage/DNA Repair>> Nucleoside Antimetabolite/Analogue>>Ganciclovir sodium

Ganciclovir sodium Sale

(Synonyms: 更昔洛韦钠,BW 759 sodium; 2'-Nor-2'-deoxyguanosine sodium) 目录号 : GC60865

An antiviral drug that is effective against CMV

Ganciclovir sodium Chemical Structure

Cas No.:107910-75-8

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥574.00
现货
100mg
¥522.00
现货
1g
¥792.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Ganciclovir is a synthetic analog of 2'-deoxy-guanosine which is used to treat or prevent cytomegalovirus (CMV) infections.1,2 It inhibits the replication of human CMV with an IC50 value of 0.01 μM and is effective against strains of CMV from human, monkey, mouse, and guinea pig.3,4

1.Balfour, H.H., Jr.Management of cytomegalovirus disease with antiviral drugsRev. Infect. Dis.12(Suppl. 7)S849-S860(1990) 2.Bean, B.Antiviral therapy: Current concepts and practicesClin. Microbiol. Rev.5(2)146-182(1992) 3.Rasmussen, L., Chen, P.T., Mullenax, J.G., et al.Inhibition of human cytomegalovirus replication by 9-(1,3-dihydroxy-2-propoxymethyl)guanine alone and in combination with human interferonsAntimicrob. Agents Chemother.26(4)441-445(1984) 4.Freitas, V.R., Smee, D.F., Chernow, M., et al.Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegalovirusesAntimicrob. Agents Chemother.28(2)240-245(1985)

Chemical Properties

Cas No. 107910-75-8 SDF
别名 更昔洛韦钠,BW 759 sodium; 2'-Nor-2'-deoxyguanosine sodium
Canonical SMILES OCC(OCN1C=NC2=C1NC(N)N=C2O[Na])CO
分子式 C9H14N5NaO4 分子量 279.23
溶解度 Water: 50 mg/mL (179.06 mM); DMSO: 5 mg/mL (17.91 mM) 储存条件 Store at 4°C, protect from light
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 3.5813 mL 17.9064 mL 35.8128 mL
5 mM 0.7163 mL 3.5813 mL 7.1626 mL
10 mM 0.3581 mL 1.7906 mL 3.5813 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Stability of Ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days

Am J Hosp Pharm 1992 Jan;49(1):116-8.PMID:1570851doi

The stability of ganciclovir 1 and 5 mg/mL in 5% dextrose injection and in 0.9% sodium chloride injection was studied at 25 degrees C and 5 degrees C over 35 days. Ganciclovir (as the sodium salt) was added to 120 polyvinyl chloride bags containing either 5% dextrose injection or 0.9% sodium chloride injection to attain ganciclovir concentrations of 1 and 5 mg/mL. Thirty bags were prepared for each combination of drug concentration and i.v. solution. Half of the bags in each group were stored at 25 degrees C; the other half were stored at 5 degrees C. Samples withdrawn from all 120 bags immediately after preparation were frozen for later determination of initial concentration. At 7, 14, 21, 28, and 35 days after preparation, approximately 5-mL samples representing each test condition were withdrawn for analysis. The samples were visually examined, tested for pH, and assayed by high-performance liquid chromatography. There was no significant loss of ganciclovir under any of the study conditions over 35 days. All solutions were clear throughout the study period. The pH decreased slightly in both diluents at both ganciclovir concentrations but did not deviate from the manufacturer's range (9-11). Admixtures containing ganciclovir 1 and 5 mg/mL (as the sodium salt) in 5% dextrose injection and 0.9% sodium chloride injection were stable in polyvinyl chloride bags stored at 25 degrees C and 5 degrees C for 35 days.

Stability of Ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections

Am J Hosp Pharm 1986 Nov;43(11):2810-2.PMID:3492139doi

The stability of 9-[(1,3-dihydroxy-2-propoxymethyl]) guanine sodium (Ganciclovir sodium, also known as DHPG sodium) in two infusion solutions was studied. Lyophilized Ganciclovir sodium 500 mg was reconstituted with sterile water 10 mL to give a theoretical concentration of 50 mg/mL. After reconstitution, 6-mL aliquots of the solution were added to 100 mL of 0.9% sodium chloride injection or 5% dextrose injection in polyvinyl chloride i.v. bags. One sample was withdrawn from each of 10 bags of each solution and analyzed by high-performance liquid chromatography (HPLC). Thirty bags of each solution were then stored under each of the following conditions: at room temperature under laboratory light, at room temperature in the dark, and under refrigeration for up to five days. Single potency assays were performed by HPLC on each of three bags of solution at three and five days after initial dilution of the solutions. The solutions were visually inspected, and the pH of the solutions was measured. All solutions of ganciclovir were stable for at least five days under all storage conditions; mean ganciclovir concentrations did not drop below 98% of initial theoretical values throughout the storage period. No important changes in the pH of the solutions occurred during the study period. Under the conditions of this study, Ganciclovir sodium is stable for up to five days when prepared in 5% dextrose injection or 0.9% sodium chloride injection.

Stability of Ganciclovir sodium and amino acids in parenteral nutrient solutions

Am J Hosp Pharm 1994 Feb 15;51(4):503-8.PMID:8017417doi

The stability of Ganciclovir sodium and amino acids in parenteral nutrient solutions was studied. Three admixtures of Ganciclovir sodium plus parenteral nutrient solution were prepared, one containing Ganciclovir sodium 0.83 mg/mL, 1% amino acids, and 10% dextrose injection; one containing Ganciclovir sodium 1.4 mg/mL, 2.5% amino acids, and 10% dextrose injection; and one containing Ganciclovir sodium 1.4 mg/mL, 5% amino acids, and 25% dextrose injection. The solutions were visually inspected for precipitates, color change, and gas formation and were tested for pH. High-performance liquid chromatography was used to measure the concentration of ganciclovir and 16 amino acids in each admixture immediately and one, two, and three hours after preparation. There was no evidence of visual incompatibility in any of the admixtures, and pH did not vary appreciably during the study. The mean Ganciclovir sodium concentration remaining was greater than 100% of the initial concentration for all the admixtures at one, two, and three hours. The mean amino acid concentration remaining in the admixtures with 2.5% or 5.0% amino acids was greater than 90% of the initial concentration for each amino acid at one, two, and three hours. The mean amino acid concentration remaining in the admixture with 1% amino acids was greater than 90% of the initial level at one and two hours. Ganciclovir sodium 0.83 mg/mL was stable for at least three hours in parenteral nutrient solution with 1% amino acids, and Ganciclovir sodium 1.4 mg/mL was stable for at least three hours in admixtures with 2.5% or 5% amino acids.(ABSTRACT TRUNCATED AT 250 WORDS)

Stability and compatibility of Ganciclovir sodium in 5% dextrose injection over 35 days

Am J Hosp Pharm 1991 Dec;48(12):2641-3.PMID:1814209doi

The stability and compatibility of Ganciclovir sodium in 5% dextrose injection over 35 days were assessed. Nine admixtures of Ganciclovir sodium 1, 5, and 10 mg/mL in 5% dextrose injection were aseptically prepared. Immediately thereafter, six samples were aseptically withdrawn from each admixture into sterile collection tubes. Three of the samples were frozen for stability-indicating high-performance liquid chromatographic (HPLC) assay at a later date, and the other three were immediately assessed for pH. Each admixture was also assessed visually for color change, turbidity, gas evolution, and precipitation. The admixtures were stored in the dark at 4-8 degrees C and sampled at 10 and 35 days. There was no significant loss of ganciclovir over the 35-day study period. No admixture at any time contained less than 93.4% or more than 103.7% of its initial ganciclovir concentration. There were no appreciable pH changes, and there was no evidence of visual incompatibility. Ganciclovir sodium 1, 5, and 10 mg/mL in 5% dextrose injection was stable for at least 35 days when stored in the dark at 4-8 degrees C.

Pharmacokinetics of ganciclovir and valganciclovir in the adult horse

J Vet Pharmacol Ther 2013 Oct;36(5):441-9.PMID:23301502DOI:10.1111/jvp.12029.

Equine herpes myeloencephalopathy, resulting from equine herpes virus type 1 (EHV-1) infection, is associated with substantial morbidity and mortality in the horse. As compared to other antiviral drugs, such as acyclovir, ganciclovir has enhanced potency against EHV-1. This study investigated the pharmacokinetics of ganciclovir and its oral prodrug, valganciclovir, in six adult horses in a randomized cross-over design. Ganciclovir sodium was administered intravenously as a slow bolus at a dose of 2.5 mg/kg, and valganciclovir was administered orally at a dose of 1800 mg per horse. Intravenously administered ganciclovir disposition was best described by a three-compartment model with a prolonged terminal half-life of 72 ± 9 h. Following the oral administration of valganciclovir, the mean observed maximum serum ganciclovir concentration was 0.58 ± 0.37 μg/mL, and bioavailability of ganciclovir from oral valganciclovir was 41 ± 20%. Superposition predicted that oral dosing of 1800-mg valganciclovir two times daily would fail to produce and maintain effective plasma concentrations of ganciclovir. However, superposition suggested that i.v. administration of ganciclovir at 2.5 mg/kg every 8 h for 24 h followed by maintenance dosing of 2.5 mg/kg every 12 h would maintain effective ganciclovir serum concentrations in most horses throughout the dosing interval.